AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Io Biotech shares rise 16.41% premarket after reporting clinical improvement in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA®.
ByAinvest
Friday, Aug 15, 2025 5:37 am ET1min read
Io Biotech, Inc. rose 16.41% in premarket trading, driven by positive news from its second quarter 2025 financial results. The company reported clinical improvement in progression-free survival in its pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® for the treatment of first-line advanced melanoma. Additionally, the company's cash position, bolstered by €12.5 million in proceeds from the European Investment Bank loan facility, is expected to sustain operations into the first quarter of 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet